Kalindi Parmar

5PUBLICATIONS
72CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 06, 2026
DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy.

|Feb 13, 2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun

|Jun 17, 2024
Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity.

Alexandre A da Costa, Ozge Somuncu, Ramya Ravindranathan

|Oct 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.

Brandon M Huffman, Hanrong Feng, Kalindi Parmar

|Aug 16, 2022
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.

Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai

Pageof 1

Frequent Collaborators

5 joint publications

Geoffrey I Shapiro

5 joint publications

Alan D D'Andrea

3 joint publications

Bose S Kochupurakkal

3 joint publications

Huy Nguyen